Contraline: Funding, Investors & Team (Sep 2026)
Contraline is a medical device company that has developed a proprietary injectable hydrogel platform for use in reproductive and contraceptive applications. Contraline's first product, Adam, is implanted into the vas deferens through a minimally invasive, outpatient procedure and once implanted, the gel effectively blocks sperm. Adam is non-hormonal, designed to last years, and easily reversible.
Contraline has raised $110M across 3 funding rounds on record, the most recent a Series B of $92.5M announced in Jun 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Contraline Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Contraline Funding Rounds
Contraline raised $10.7M in a Series A announced in Oct 2021.
1.1 years later, a Series A of $7.2M was announced in Nov 2022.
3.6 years later, a Series B of $92.5M was announced in Jun 2026.
Contraline Founders and Leadership Team
Contact details for the Contraline team: 1 of 1 has an email address on file.
Start 14-day free trial →Contraline Funding Compared to Other Biotechnology Startups
Contraline's latest round of $92.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Contraline in Biotechnology and Charlottesville
Companies Similar to Contraline
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Contraline Funding FAQs
What does Contraline do?
Contraline is a medical device company that has developed a proprietary injectable hydrogel platform for use in reproductive and contraceptive applications. Contraline's first product, Adam, is implanted into the vas deferens through a minimally invasive, outpatient procedure and once implanted, the gel effectively blocks sperm. Adam is non-hormonal, designed to last years, and easily reversible.
How much funding has Contraline raised?
Contraline has raised $110M across 3 rounds on record. The most recent is a Series B of $92.5M announced in Jun 2026.
When did Contraline last raise funding?
Contraline's most recent funding round on record is a Series B of $92.5M, announced in Jun 2026.
Who is the CEO of Contraline?
Kevin Eisenfrats is listed as CEO at Contraline.
Where is Contraline headquartered?
Contraline is based in Charlottesville, Virginia, United States.
How many employees does Contraline have?
Contraline is in the 11-50 employee band.
How does Contraline's funding compare to other Biotechnology startups?
Contraline's latest round of $92.5M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Contraline Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Contraline is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.